Abstract
Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors affecting the regulation of various genes relevant to the pathogenesis of diabetic complications. A number of drugs have been developed to act as agonists of the three PPARs. To date, PPAR isoforms that have been identified are the α, β/δ, and γ isosforms. Fenofibrate and gemfibrozil are two drugs that act as PPARα agonists and are currently in use in the clinical setting. Rosiglitazone is a PPARγ agonist also in clinical use. These drugs have proved very useful in regulation of either glucose or lipid metabolism and consequently are used in patients with type 2 diabetes. Here, we will review the anti-atherosclerotic potential of PPAR agonists with particular emphasis on recent studies in an animal model of diabetes-associated atherosclerosis, the streptozotocin diabetic apolipoprotein E deficient mouse. These studies have shown both PPARα agonists, gemfibrozil and fenofibrate, confer anti-atherosclerotic effects, partly independent of their metabolic effects. Similar positive findings have also been detected in a dose-dependent manner with the PPARγ agonist, rosiglitazone. The potential clinical implications of these findings are also discussed in view of the recently reported results of the PROACTIVE and FIELD clinical trials with the PPAR agonists rosiglitazone and fenofibrate respectively..
Keywords: PPAR, Diabetes, atherosclerosis, rosiglitazone, fenofibrate
Current Pharmaceutical Design
Title: PPARs and Diabetes-Associated Atherosclerosis
Volume: 13 Issue: 26
Author(s): A. C. Calkin, K. A. Jandeleit-Dahm, T. J. Allen, J. Mizrahi, M. E. Cooper, C. Tikellis and E. Sebokova
Affiliation:
Keywords: PPAR, Diabetes, atherosclerosis, rosiglitazone, fenofibrate
Abstract: Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription factors affecting the regulation of various genes relevant to the pathogenesis of diabetic complications. A number of drugs have been developed to act as agonists of the three PPARs. To date, PPAR isoforms that have been identified are the α, β/δ, and γ isosforms. Fenofibrate and gemfibrozil are two drugs that act as PPARα agonists and are currently in use in the clinical setting. Rosiglitazone is a PPARγ agonist also in clinical use. These drugs have proved very useful in regulation of either glucose or lipid metabolism and consequently are used in patients with type 2 diabetes. Here, we will review the anti-atherosclerotic potential of PPAR agonists with particular emphasis on recent studies in an animal model of diabetes-associated atherosclerosis, the streptozotocin diabetic apolipoprotein E deficient mouse. These studies have shown both PPARα agonists, gemfibrozil and fenofibrate, confer anti-atherosclerotic effects, partly independent of their metabolic effects. Similar positive findings have also been detected in a dose-dependent manner with the PPARγ agonist, rosiglitazone. The potential clinical implications of these findings are also discussed in view of the recently reported results of the PROACTIVE and FIELD clinical trials with the PPAR agonists rosiglitazone and fenofibrate respectively..
Export Options
About this article
Cite this article as:
Calkin C. A., Jandeleit-Dahm A. K., Allen J. T., Mizrahi J., Cooper E. M., Tikellis C. and Sebokova E., PPARs and Diabetes-Associated Atherosclerosis, Current Pharmaceutical Design 2007; 13 (26) . https://dx.doi.org/10.2174/138161207781662902
DOI https://dx.doi.org/10.2174/138161207781662902 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Network Pharmacology and Molecular Docking Approaches to Investigating the Mechanism of Action of <i>Zanthoxylum bungeanum</i> in the Treatment of Oxidative Stress-induced Diseases
Combinatorial Chemistry & High Throughput Screening Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Potential Impact of Genetic Variants in Nrf2 Regulated Antioxidant Genes and Risk Prediction of Diabetes and Associated Cardiac Complications
Current Medicinal Chemistry Aldose Reductase: A Multi-disease Target
Current Enzyme Inhibition Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson’s Disease
Current Medicinal Chemistry Interval Exercise Therapy for Type 2 Diabetes
Current Diabetes Reviews Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Dysregulation of Neurotrophic and Haematopoietic Growth Factors in Alzheimer’s Disease: From Pathophysiology to Novel Treatment Strategies
Current Alzheimer Research Role of Endothelin in Diabetic Retinopathy
Current Vascular Pharmacology Editorial: Structural Aspects of Protein Aggregation
Protein & Peptide Letters Prospective Function of Different Antioxidant Containing Natural Products in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Oxidative Stress and Skeletal Muscle Dysfunction with Aging
Current Aging Science Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Polyglutamine and Neurodegeneration: Structural Aspects
Protein & Peptide Letters Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Investigation of Chemical Compounds, Antioxidant and Antimicrobial Properties of Teucrium arduini L. (Lamiaceae)
Current Drug Targets